

**AMENDMENTS TO THE CLAIMS**

Please replace the currently pending claims with the following listing of claims:

1-42. (Canceled)

43. (Currently amended) A method of inhibiting proliferation ~~modulating growth~~ of tumor cells ~~in vivo~~ in a subject comprising the step of administering to the subject an effective amount of a composition comprising ~~an~~ a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier.

44. (Previously presented) The method according to claim 43, wherein the subject is human.

45. (Currently amended) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising ~~an~~ a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier in an effective amount.

46. (Currently amended) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising ~~an~~ a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 in an effective amount.

47. (Currently Amended) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising ~~an~~ a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID No:1 or SEQ ID NO:2 in an effective amount.

48. **(Currently Amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising ~~an~~ a monoclonal antibody which binds specifically to an epitope selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, B3F6.17, and B11H8.4 bind in an effective amount.

49. **(Canceled)**

50. **(Previously Presented)** The method according to claim 43, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

51-58. **(Canceled)**

59. **(Previously presented)** The method of claim 43, wherein the antibody is a humanized antibody.

60. **(Previously presented)** The method of claim 43, wherein the antibody is a human antibody.

61. **Canceled.**

62 **(Previously presented)** The method of claim 43, wherein the antibody specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2.

63. **(Previously presented)** The method of claim 43, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')<sub>2</sub> fragment.

64. **(Previously presented)** The method of claim 43, wherein the antibody is a full length antibody.

65. **(Previously presented)** The method of claim 43, wherein the antibody is a single chain antibody.

66. **(Previously presented)** The method of claim 43, wherein the antibody is conjugated to a chemotherapeutic agent.

67. **(Currently amended)** The method of claim 43, wherein the antibody is administered in combination with a ~~nonconjugated~~ chemotherapeutic agent which is not conjugated to the antibody.

68. **(Previously presented)** The method of claim 66, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

69. **(Previously presented)** The antibody of claim 68, wherein the agent is a maytansinoid.

70. **(Previously presented)** The method of claim 43 wherein the antibody specifically binds to an epitope comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2 which antibody or fragment is conjugated to a maytansinoid and a pharmaceutically acceptable carrier.

71. **(Previously presented)** The method of claim 43, wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.

72. **(Previously presented)** The method of claim 43, wherein the antibody binds an epitope selected from the group of epitopes to which antibodies produced by hybridomas selected from the group consisting of A10B2.18 and B3F6.17 bind.

73. **(Previously presented)** The method of claim 43, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 which is capable of internalizing Cripto.

74. **(Previously presented)** The method of claim 43, wherein the antibody specifically binds to an epitope comprised in the cysteine-rich domain of Cripto

spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID NO:1 or SEQ ID NO:2.

75. **(Previously presented)** The method of claim 43, wherein the antibody binds an epitope selected from the group of epitopes to which antibodies produced by hybridomas selected from the group consisting of A6.C12.11, A8G3.5, and A6F8.6 bind.

76. **(Previously presented)** The method of claim 43, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 which inhibits the interaction of Cripto and ALK4.

77. **(Previously presented)** The method of claim 43, wherein the antibody binds specifically to an epitope selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, B3F6.17, and B11H8.4 bind.

78. **(Currently amended)** The method of claim 43, wherein the antibody binds to an epitope comprised in the extracellular domain spanning amino acid residues ~~77-111~~ 31-188 of SEQ ID NO:1 or SEQ ID NO:2.

79. **(New)** The method of claim 43, wherein the antibody binds to an epitope comprised in the ligand-receptor binding domain spanning amino acid residues 75-150 of SEQ ID NO:1 or SEQ ID NO:2.

80. **(New)** The method of claim 43, wherein the antibody binds to an epitope comprised in the EGF-like domain spanning amino acid residues 75-112 of SEQ ID NO:1 or SEQ ID NO:2.